Does the media favor HSIC or DGX?

In the previous week, Henry Schein had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 6 mentions for Henry Schein and 3 mentions for Quest Diagnostics. Henry Schein's average media sentiment score of 0.89 beat Quest Diagnostics' score of 0.44 indicating that Henry Schein is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, DGX or MEDP?

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quest Diagnostics $11.04B 2.33 $992M $9.42 24.77 Medpace $2.78B 6.01 $451.12M $17.06 35.14

Is DGX or MEDP more profitable?

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Quest Diagnostics 9.18% 16.01% 7.27% Medpace 17.67% 110.15% 24.84%

Does the media refer more to DGX or MEDP?

In the previous week, Medpace had 23 more articles in the media than Quest Diagnostics. MarketBeat recorded 26 mentions for Medpace and 3 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.44 beat Medpace's score of 0.36 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 9 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AMN or DGX?

In the previous week, AMN Healthcare Services and AMN Healthcare Services both had 3 articles in the media. AMN Healthcare Services' average media sentiment score of 0.83 beat Quest Diagnostics' score of 0.44 indicating that AMN Healthcare Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AMN Healthcare Services 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quest Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DGX or LH?

In the previous week, Labcorp had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 6 mentions for Labcorp and 3 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.44 beat Labcorp's score of 0.41 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Labcorp 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DGX or CI?

In the previous week, Cigna Group had 21 more articles in the media than Quest Diagnostics. MarketBeat recorded 24 mentions for Cigna Group and 3 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.44 beat Cigna Group's score of 0.43 indicating that Quest Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quest Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cigna Group 4 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Quest Diagnostics (DGX) Competitors

$233.32 +2.23 (+0.96%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$230.32 -3.00 (-1.28%)

As of 10/2/2026 07:34 PM Eastern

Compare

DGX vs. HSIC, MEDP, AMN, LH, and CI

Should you buy Quest Diagnostics stock or one of its competitors? Quest Diagnostics's main competitors and comparable companies include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), and Cigna Group (CI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Quest Diagnostics compare to Henry Schein?

Henry Schein (NASDAQ:HSIC) and Quest Diagnostics (NYSE:DGX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Henry Schein presently has a consensus price target of $92.93, indicating a potential upside of 9.49%. Quest Diagnostics has a consensus price target of $237.08, indicating a potential upside of 1.61%. Given Henry Schein's higher probable upside, equities research analysts plainly believe Henry Schein is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54

Quest Diagnostics has lower revenue, but higher earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18B	0.72	$398M	$3.43	24.75
Quest Diagnostics	$11.04B	2.33	$992M	$9.42	24.77

96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 0.9% of Henry Schein shares are owned by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Quest Diagnostics has a net margin of 9.18% compared to Henry Schein's net margin of 2.96%. Quest Diagnostics' return on equity of 16.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.96%	15.97%	5.56%
Quest Diagnostics	9.18%	16.01%	7.27%

Henry Schein has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

In the previous week, Henry Schein had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 6 mentions for Henry Schein and 3 mentions for Quest Diagnostics. Henry Schein's average media sentiment score of 0.89 beat Quest Diagnostics' score of 0.44 indicating that Henry Schein is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Quest Diagnostics beats Henry Schein on 9 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Medpace?

Quest Diagnostics (NYSE:DGX) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Quest Diagnostics currently has a consensus price target of $237.08, suggesting a potential upside of 1.61%. Medpace has a consensus price target of $602.27, suggesting a potential upside of 0.47%. Given Quest Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.33	$992M	$9.42	24.77
Medpace	$2.78B	6.01	$451.12M	$17.06	35.14

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Medpace has a net margin of 17.67% compared to Quest Diagnostics' net margin of 9.18%. Medpace's return on equity of 110.15% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Medpace	17.67%	110.15%	24.84%

Quest Diagnostics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

In the previous week, Medpace had 23 more articles in the media than Quest Diagnostics. MarketBeat recorded 26 mentions for Medpace and 3 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.44 beat Medpace's score of 0.36 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	9 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Medpace beats Quest Diagnostics on 9 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Quest Diagnostics (NYSE:DGX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

In the previous week, AMN Healthcare Services and AMN Healthcare Services both had 3 articles in the media. AMN Healthcare Services' average media sentiment score of 0.83 beat Quest Diagnostics' score of 0.44 indicating that AMN Healthcare Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.52	-$95.70M	$2.68	13.70
Quest Diagnostics	$11.04B	2.33	$992M	$9.42	24.77

AMN Healthcare Services currently has a consensus price target of $36.00, indicating a potential downside of 1.95%. Quest Diagnostics has a consensus price target of $237.08, indicating a potential upside of 1.61%. Given Quest Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Quest Diagnostics is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AMN Healthcare Services has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Quest Diagnostics has a net margin of 9.18% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	3.06%	19.92%	5.93%
Quest Diagnostics	9.18%	16.01%	7.27%

Summary

Quest Diagnostics beats AMN Healthcare Services on 12 of the 16 factors compared between the two stocks.

How does Quest Diagnostics compare to Labcorp?

Quest Diagnostics (NYSE:DGX) and Labcorp (NYSE:LH) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Quest Diagnostics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Quest Diagnostics has higher earnings, but lower revenue than Labcorp. Quest Diagnostics is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.33	$992M	$9.42	24.77
Labcorp	$13.95B	1.79	$876.50M	$12.09	25.52

Quest Diagnostics currently has a consensus price target of $237.08, suggesting a potential upside of 1.61%. Labcorp has a consensus price target of $337.73, suggesting a potential upside of 9.45%. Given Labcorp's stronger consensus rating and higher probable upside, analysts clearly believe Labcorp is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Labcorp	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75

Quest Diagnostics has a net margin of 9.18% compared to Labcorp's net margin of 6.99%. Labcorp's return on equity of 16.74% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Labcorp	6.99%	16.74%	7.81%

In the previous week, Labcorp had 3 more articles in the media than Quest Diagnostics. MarketBeat recorded 6 mentions for Labcorp and 3 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.44 beat Labcorp's score of 0.41 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Labcorp	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by company insiders. Comparatively, 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.5%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Labcorp pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 14 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Labcorp beats Quest Diagnostics on 12 of the 20 factors compared between the two stocks.

How does Quest Diagnostics compare to Cigna Group?

Quest Diagnostics (NYSE:DGX) and Cigna Group (NYSE:CI) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, Cigna Group had 21 more articles in the media than Quest Diagnostics. MarketBeat recorded 24 mentions for Cigna Group and 3 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.44 beat Cigna Group's score of 0.43 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cigna Group	4 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.5%. Cigna Group pays an annual dividend of $6.24 per share and has a dividend yield of 2.3%. Quest Diagnostics pays out 36.5% of its earnings in the form of a dividend. Cigna Group pays out 25.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has raised its dividend for 14 consecutive years and Cigna Group has raised its dividend for 5 consecutive years. Cigna Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Quest Diagnostics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Cigna Group has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Cigna Group has higher revenue and earnings than Quest Diagnostics. Cigna Group is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.04B	2.33	$992M	$9.42	24.77
Cigna Group	$274.90B	0.26	$5.96B	$24.17	11.21

Quest Diagnostics presently has a consensus price target of $237.08, suggesting a potential upside of 1.61%. Cigna Group has a consensus price target of $338.24, suggesting a potential upside of 24.85%. Given Cigna Group's stronger consensus rating and higher possible upside, analysts plainly believe Cigna Group is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.54
Cigna Group	0 Sell rating(s)	8 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.65

Quest Diagnostics has a net margin of 9.18% compared to Cigna Group's net margin of 2.27%. Cigna Group's return on equity of 19.75% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.18%	16.01%	7.27%
Cigna Group	2.27%	19.75%	5.34%

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 87.0% of Cigna Group shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 0.6% of Cigna Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Quest Diagnostics and Cigna Group tied by winning 10 of the 20 factors compared between the two stocks.

Get Quest Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DGX vs. The Competition

Export

Metric	Quest Diagnostics	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$25.51B	$9.59B	$7.14B	$22.64B
Dividend Yield	1.48%	2.61%	2.53%	3.73%
P/E Ratio	24.77	34.21	275.68	27.75
Price / Sales	2.23	5.39	662.25	96.41
Price / Cash	15.23	120.59	77.60	38.88
Price / Book	3.60	5.15	10.93	4.64
Net Income	$992M	$315.68M	$3.51B	$1.08B
7 Day Performance	-1.21%	-2.59%	-2.00%	-1.06%
1 Month Performance	-2.62%	-3.19%	-6.15%	-5.49%
1 Year Performance	30.29%	7.93%	7.44%	5.13%

Quest Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DGX Quest Diagnostics	3.8283 of 5 stars	$233.32 +1.0%	$237.08 +1.6%	+29.0%	$25.51B	$11.56B	24.77	57,000
HSIC Henry Schein	3.6434 of 5 stars	$85.99 -0.4%	$92.93 +8.1%	+28.5%	$9.63B	$13.18B	25.07	25,000	Positive News
MEDP Medpace	2.3927 of 5 stars	$615.94 -0.5%	$595.20 -3.4%	+11.8%	$17.27B	$2.53B	36.10	6,200	Trending News Analyst Upgrade Insider Trade
AMN AMN Healthcare Services	1.2597 of 5 stars	$34.20 -1.0%	$36.00 +5.3%	+87.8%	$1.34B	$2.73B	12.76	2,664
LH Labcorp	4.0666 of 5 stars	$309.85 +0.1%	$337.73 +9.0%	+10.6%	$25.11B	$13.95B	25.63	71,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DGX) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and CI

How does Quest Diagnostics compare to Henry Schein?

Summary

How does Quest Diagnostics compare to Medpace?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Summary

How does Quest Diagnostics compare to Labcorp?

Summary

How does Quest Diagnostics compare to Cigna Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and CI

How does Quest Diagnostics compare to Henry Schein?

Do analysts prefer HSIC or DGX?

Which has stronger valuation and earnings, HSIC or DGX?

Do insiders and institutionals believe in HSIC or DGX?

Is HSIC or DGX more profitable?

Which has more volatility & risk, HSIC or DGX?

Does the media favor HSIC or DGX?

Summary

How does Quest Diagnostics compare to Medpace?

Do analysts recommend DGX or MEDP?

Which has higher valuation & earnings, DGX or MEDP?

Do insiders & institutionals hold more shares of DGX or MEDP?

Is DGX or MEDP more profitable?

Which has more volatility & risk, DGX or MEDP?

Does the media refer more to DGX or MEDP?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Does the media favor AMN or DGX?

Which has higher earnings & valuation, AMN or DGX?

Do analysts recommend AMN or DGX?

Do insiders and institutionals believe in AMN or DGX?

Which has more risk & volatility, AMN or DGX?

Is AMN or DGX more profitable?

Summary

How does Quest Diagnostics compare to Labcorp?

Which has more risk & volatility, DGX or LH?

Which has better earnings & valuation, DGX or LH?

Do analysts recommend DGX or LH?

Is DGX or LH more profitable?

Does the media favor DGX or LH?

Do insiders & institutionals believe in DGX or LH?

Is DGX or LH a better dividend stock?

Summary

How does Quest Diagnostics compare to Cigna Group?

Does the media refer more to DGX or CI?

Is DGX or CI a better dividend stock?

Which has more volatility & risk, DGX or CI?

Which has stronger valuation & earnings, DGX or CI?

Do analysts prefer DGX or CI?

Is DGX or CI more profitable?

Do insiders and institutionals have more ownership in DGX or CI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools